Strengths of this study include its comparison to age and gender matched healthy controls, as well as its simultaneous evaluation of multiple neuropathologies, including AD, TSC, FTLD-tau, and other neurodegenerative disorders. The gene discussed is MAPT; the disease is Alzheimer disease.